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Abstract
Background: It is believed that schistosomes evade complement-mediated killing by expressing regulatory proteins on
their surface. Recently, six homologues of human CD59, an important inhibitor of the complement system membrane attack
complex, were identified in the schistosome genome. Therefore, it is important to investigate whether these molecules
could act as CD59-like complement inhibitors in schistosomes as part of an immune evasion strategy.
Methodology/Principal Findings: Herein, we describe the molecular characterization of seven putative SmCD59-like genes
and attempt to address the putative biological function of two isoforms. Superimposition analysis of the 3D structure of
hCD59 and schistosome sequences revealed that they contain the three-fingered protein domain (TFPD). However, the
conserved amino acid residues involved in complement recognition in mammals could not be identified. Real-time RT-PCR
and Western blot analysis determined that most of these genes are up-regulated in the transition from free-living cercaria to
adult worm stage. Immunolocalization experiments and tegument preparations confirm that at least some of the SmCD59-
like proteins are surface-localized; however, significant expression was also detected in internal tissues of adult worms.
Finally, the involvement of two SmCD59 proteins in complement inhibition was evaluated by three different approaches: (i)
a hemolytic assay using recombinant soluble forms expressed in Pichia pastoris and E. coli; (ii) complement-resistance of
CHO cells expressing the respective membrane-anchored proteins; and (iii) the complement killing of schistosomula after
gene suppression by RNAi. Our data indicated that these proteins are not involved in the regulation of complement
activation.
Conclusions: Our results suggest that this group of proteins belongs to the TFPD superfamily. Their expression is associated
to intra-host stages, present in the tegument surface, and also in intra-parasite tissues. Three distinct approaches using
SmCD59 proteins to inhibit complement strongly suggested that these proteins are not complement inhibitors and their
function in schistosomes remains to be determined.
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Introduction
Schistosomiasis is an important parasitic disease, caused by
trematode worms of the genus Schistosoma, affecting more than 200
million people worldwide, with a further 650 million individuals
living at risk of infection, remaining a major public health problem
in many developing countries [1].
Adult worms are able to survive for decades in the hostile blood
environment of their vertebrate host, apparently unharmed by
circulating leukocytes, antibodies and the complement system.
Thus, the parasite must have developed strategies to evade the
host’s immune defenses. One of the most important modifications
is the new tegument surface organization that develops immedi-
ately after penetration of cercariae into the skin and their
transformation into schistosomula. The tegument is a thin
syncytial layer that covers the whole parasite, limited by a basal
membrane and a multilaminate surface membrane complex,
which constitutes the major host–parasite interface [2].
Schistosomula are at first sensitive to complement killing, but
rapidly become highly resistant to complement attack by both the
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Classical [3,4] and Alternative Pathways [5,6]. The later
developmental stages of the parasite, i.e., the lung schistosomula
and adult worms, have also been shown to be refractory to both
pathways of complement [3,6,7,8]. Intravascular parasites must
also be resistant to a third complement activation pathway - the
Lectin Pathway [9]. However, the precise mechanisms of
complement resistance have not been fully characterized.
The strategies used by the parasite to subvert complement
attack are most likely related to the function and composition of
the tegument (reviewed by [10]). The apical membrane is
considered poorly immunogenic due to the limited number of
exposed proteins and the acquisition of a variety of host
molecules, which may mask important surface proteins
[11,12,13]. Shedding of the outer coat has been considered as
a mechanism to eliminate surface-bound complement and
immune-complexes [14]. There are also reports of serine
proteases in the surface of freshly transformed schistosomula,
lung stage and adult worms, that may play a role in complement
resistance by cleaving immuno-complexes and complement
proteins [15,16].
One of the most intriguing strategies that has been proposed as
a mechanism by which schistosomes escape complement attack
involves the presence in the tegument of several complement
regulatory proteins, including two of host origin (reviewed by
[17,18]). The binding activity to the complement components C1
[19,20], C3 [21,22,23] and C8/C9 [24], have been reported to be
present at the surface of schistosome parasites. It is important to
note that while some of these parasite proteins (e.g. paramyosin)
have been isolated and shown to interact with complement
components in vitro, the definitive protective role of these proteins
in vivo has not yet been demonstrated.
In the last seven years, several proteomics studies attempted to
define the tegument protein composition, as well as its surface
exposed molecules [25]. From these studies, one surprising finding
was the detection of the host complement components C3 and C4,
but not those required for formation of the Membrane Attack
Complex (MAC), i.e. C5b to C9 molecules, as revealed by
biotinylation studies of the tegument surface [12]. A reasonable
explanation is that the complement fixation is initiated, but then
inhibited to prevent MAC formation. A mouse C3 complement
regulatory (Crry)-like molecule has also been detected on the
tegument surface by proteomics [12].
Host cells are protected from MAC-mediated lysis mainly by
CD59, a 18–21 kDa glycosylphosphatidyl-inositol-linked mem-
brane glycoprotein that inhibits polymerization of C9 by
binding to C8a and C9 [26], thus preventing the formation of
the cytolytic MAC. Earlier studies indicated that the exposed
form of the schistosome muscle protein paramyosin, was able
to inhibit the assembly of C5b-9 by binding to C8 and C9;
additionally, this protein was reportedly recognized by rabbit
anti-human CD59 antiserum [27]. However, the in vivo
significance of paramyosin-complement interactions still awaits
further clarification.
Recently, Wilson and Coulson [28] identified in the
schistosome genome six homologues of human CD59,
containing 20–30% amino acid identity which rise to .40%
if conservative amino acid substitutions are included. One of
these molecules (CD59b, formerly Dif 5) was described by our
group as a vaccine candidate, due to its up-regulated
expression in the schistosomulum stage [29]. Furthermore,
in another approach to select vaccine candidates, two
members of this family (CD59a and CD59b) were identified
within a group of molecules exposed on the parasite’s
tegument by proteomics and molecular shaving with phos-
phatidylinositol-specific phospholipase C (PiPL-C) treatment of
live adult worms [13]. More recently, two other isoforms
similar to CD59 (Smp_166340 and Smp_081920, GeneDB,
(http://www.genedb.org/Homepage/Smansoni) were reported
as membrane-associated tegumental proteins by proteomic
analysis [25]. Therefore, it is tempting to speculate whether
these six homologues could act as CD59-like complement
inhibitors in schistosomes as part of an immune evasion
strategy, especially because two of them were found on the
tegument surface.
The CD59 family possesses the Three-Finger Protein
Domain fold (TFPD) [30], that is also a feature of proteins
with several distinct sequence and structural attributes, such as
the receptors of activins, bone morphogenetic proteins,
Mullerian inhibiting substance, transforming growth factor-b
receptor II, C4.4a (a structural homologue of the urokinase
receptor), urokinase/plasminogen activatory receptor (uPAR)
and several members of Ly6 family. The Ly6 molecules
(lymphocyte differentiation antigens) were among the first cell
surface molecules identified in mouse [31] and there is
emerging evidence showing their role in cell signaling, cell
adhesion and cellular activation [32]. The TFPD superfamily
is characterized by the structural conservation of at least six
half-cystines forming three disulfide bridges (B1, B2 and B4),
five b-strands and one asparagine adjacent to the N-terminal
of the last half-cystine from the last disulfide bridge B4 [33].
A very striking characteristic of this domain is the finger-
shaped spatial conformation that the amino acid backbone
acquires between the two half-cystines of the same disulfide
bridge [30].
In the current work, we describe the molecular character-
ization of seven putative SmCD59-like genes from genome
assembly version 5 (http://www.genedb.org/Homepage/
Smansoni) and attempt to address their putative biological
function. Our data confirms up-regulation in the transition to
intra-host stages. However, the functional studies performed
with the two CD59-like members (CD59a and CD59b,
named in this study as SmCD59.1 and SmCD59.2),
previously identified at the host-parasite interface, did not
show any complement inhibition activity. Therefore, the
Author Summary
Schistosomes are parasites that reside for many years in
the blood stream, demanding efficient mechanisms of
evading immune response effectors such as complement
deposition. A group of genes similar to human CD59, an
important complement inhibitor in mammals, were iden-
tified in the schistosome genome. Computer predictions of
protein structure indicated substantial similarity of the
schistosome proteins and the mammalian CD59 family of
proteins, which due to their three-finger-shaped spatial
conformation are members of the Three-Finger Protein
Domain fold superfamily (TFPD). Members of this family of
schistosome proteins were also shown to be expressed
predominantly during the mammalian stages when worms
are exposed to complement and found to be present at
the host-interactive surface of schistosomes. Three differ-
ent methods were employed to test the possible involve-
ment of these proteins in complement inhibition. Our
results strongly suggest that these proteins are not
involved in the inhibition of complement and that further
studies are needed to establish their functional role(s) in
schistosomes.
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function of these seven proteins in schistosomes remains to
be established.
Materials and Methods
Parasite material
The life cycle of S. mansoni (BH strain) was maintained in the
laboratory by routine passage through mice and the intermediate
snail host Biomphalaria glabrata. S. mansoni eggs were extracted from
infected mouse livers and miracidia were hatched from S. mansoni
eggs, as previously described [34]. Schistosomula were cultivated
in culture medium after transformation of cercariae, as previously
described [35]. Adult worms were obtained by perfusion of the
portal hepatic and intestinal veins from hamsters, 7–8 weeks after
infection with approximately 100 cercariae.
Ethics statement
The procedures involving animals were carried out in accor-
dance with the Brazilian legislation (11790/2008). All animals
were handled in strict accordance with good animal practice and
protocols were previously approved by the Ethical Committee for
Animal Research of Butantan Institute (CEUAIB, Sa˜o Paulo,
Brazil), under the license number 603/09.
Molecular characterization and 3D modeling
The SmCD59 nucleotide sequences were identified searching
the v5.0 of S. mansoni genome assembly (GeneDB) (http://www.
genedb.org/genedb/smansoni/). The search for conserved do-
mains was performed using SMART (http://smart.embl-
heidelberg.de/). The molecular weight (MW) and isoelectric point
(pI) were calculated with the Compute pI/Mw tool (http://www.
expasy.ch/tools/pi_tool.html).
Post-translational modification predictions: the signal peptide
prediction was performed using the SignalP 4.0 server (http://
www.cbs.dtu.dk/services/SignalP/) [36]; potential GPI-modifica-
tion sites were analyzed by big-PI Predictor (http://mendel.imp.
ac.at/sat/gpi/gpi_server.html) [37]; and N-glycosylation sites with
the NetNGlyc version 1.0 algorithm. Protein sequences alignments
were performed using the ClustalX 2 software. Homology
modeling was done with MODELLER [38] using the crystal
structure of human CD59 (hCD59) (2UWR) as a template. The
modeled structure was visualized with PyMOL (The PyMOL
Molecular Graphics System, Version 1.5.0.4 Schro¨dinger, LLC)
and the stereochemical quality of the model was examined using
the program PROCHECK [39], which evaluates the geometry of
residues in the model when compared with the stereochemical
parameters from the template. Additional algorithms such as
WHAT_CHECK, ERRAT, VERIFY_ 3D, PROVE and
CRYST1 record matches (available from: http://services.mbi.
ucla.edu/SAVES/) were also used to assess the quality of the
model generated.
Sequence and phylogenetic analysis
We searched the Schistosoma Genomic Resources SchistoDB
(V3.0) (http://schistodb.net/schisto/) and the GenBank (http://
www.ncbi.nlm.nih.gov/) to identify similar sequences in S. mansoni,
S. japonicum and S. hematobium, using SmCD59.1 and SmCD59.2 as
queries. Additionally, BLAST and PSI-BLAST searches against
the non-redundant protein sequence database were used to
identify similar sequences in other Platyhelminthes (http://
smedgd.neuro.utah.edu/blast.php and http://bioinfosecond.vet.
unimelb.edu.au), as well as in representative mammals. For
phylogenetic analysis, alignments of protein sequences were
performed using the ClustalX 2 software. The tree was
constructed using ClustalX 2 using the Neighbor-Joining method.
The numbers represent the confidence of the branches assigned by
bootstrap (in 1000 samplings). The TreeView program [40] was
used to visualize and analyze the tree.
Real-time RT-PCR
In order to establish the level of expression of each SmCD59
gene throughout the parasite life cycle, total RNA was extracted
from adult worms using TRIzol (Life Technologies) and from
schistosomula, cercariae, miracidia and eggs using the Kit
RNAspin mini (GE Healthcare, USA), as per the manufacturer’s
recommendations. The RNA was quantified by spectrophotom-
etry (NanoDrop 1000, Thermo Fischer Scientific) and the quality
was analyzed in the Agilent 2100 Bioanalyzer. The cDNA
synthesis and the quantitative Real-Time PCR (qRT-PCR)
reactions using SYBR Green (Life Technologies) were performed
according to [41]. The primers were designed in the software
Primer Express (Applied Biosystems) to span exon/exon bound-
aries avoiding amplification of contaminating genomic DNA
(Table S1). S. mansoni alpha-tubulin (Smp_090120.1) was chosen as
normalizing gene. Quantitation of relative differences in expres-
sion between the stages was calculated by the comparative 22DDCt
method [42], using the parasite stage with lowest gene expression
as calibrator for each gene independently.
In an attempt to compare the levels of gene expression among
the seven different SmCD59 isoforms, we performed qRT-PCR
using TaqMan Gene Expression Assay (Life Technologies/
Applied Biosystems, CA) as previously described [43]. The life
cycle stages examined were cercariae, schistosomula cultured for
11 days and adults. RNA was extracted from each life cycle stage
using the Trizol method (Life Technologies, CA) and the cDNA
was synthesized using 1 mg of high quality total RNA, pre-treated
with TurboDNAse (Life Technologies), oligo(dT) and Superscript
reverse transcriptase III (Life Technologies). qRT-PCR was
performed using cDNA equivalent to 50 ng total RNA. The set
of primers and MGB reporter probe, labeled with 6-carboxy-
fluorescein (FAM) specific for the detection of each SmCD59 were
custom synthesized by Applied Biosystems (Life Technologies) and
are shown in Table S1. Primers/probe positions were designed to
span exon/exon boundaries to minimize detection of any
contaminating genomic DNA. The qRT-PCR reactions were
run in triplicate and underwent 45 amplification cycles on the
StepOne Plus System Instrument (Applied Biosystems). The
22DDCt method was employed for relative quantification [42]
with S. mansoni triose phosphate isomerase (SmTPI, Smp_003990)
as the normalizing gene. We used the expression of SmCD59.6
from adult worm stage as calibrator to calculate the relative
expression of all other SmCD59 analyzed, because this gene had
the lowest expression in adult worms.
DNA constructs - gene optimization and synthesis
The sequence from S. mansoni EST assembled contig SmCD59.2
(Smp_105220, GeneDB) was redesigned excluding the signal
peptide sequences and manufactured by DNA 2.0, Inc. USA
(https://www.dna20.com/) using DNA2.0 optimization algo-
rithms for expression in Pichia pastoris (Table S1). The fragments
corresponding to the mature protein sequences for SmCD59.1
(Smp_019350, GeneDB) (from H28 to F126) and SmCD59.2
(from K21 to A97) were digested with EcoRI and XbaI to generate
inserts with overhang ends that were purified and cloned into the
same sites for the expression vector pPICZaA (Life Technologies),
to produce a protein that contained a C-terminal hexa-histidine
tag. The resulting constructs were sequenced to confirm their
identity.
On the CD59-Like proteins in Schistosoma mansoni
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The SmCD59.2 was also expressed and purified from E. coli.
The 59 and 39 oligonucleotides were designed using the S. mansoni
genome assembly sequence (Smp_105220). The SuperScriptTM
First-Strand Synthesis System for RT-PCR (Life Technologies)
was used to amplify a fragment from C27 to H101 of the mature
SmCD59.2 protein. The PCR fragments were purified from
agarose gel electrophoresis and digested with XhoI and KpnI to be
cloned into pAE-6His vector [44] and sequenced to confirm
identity.
Expression and purification of recombinant SmCD59.1
and SmCD59.2 in Pichia pastoris
The plasmids containing the gene fragments pPICZ-a-
SmCD59.1 and pPICZ-a-SmCD59.2 (optimized sequence), were
linearized with SacI and used to transform P. pastoris strain GS115
(Life Technologies) by electroporation. Putative multi-copy
recombinants were selected following the instructions of the
manufacturer. To verify production of the relevant proteins, initial
studies were done in small-scale expression conditions, followed by
Western blot with anti-His-tag antibody (GE). Fermentation
conditions for selected clones were carried out in BMGY media
(15 mL) at 28–30uC in a shaking incubator until cultures reached
an OD600 = 2.0 (approximately 16–18 h), as per manufacturer’s
recommendations. Induction was performed by addition of
methanol to a final concentration of 0.5% every 24 h; expression
was monitored at 48 and 96 h time points. The supernatants and
cell pellets for 10 colonies of each SmCD59 were analyzed for
protein expression by Western blot. The colonies that presented
the highest expression level were selected for scale-up fermenta-
tion.
For protein expression and purification, selected clones were
scaled-up for growth in 300 mL in 2.0 L baffled flasks under the same
conditions. Cells were harvested after 96 h by centrifugation. The
culture medium containing the secreted proteins were filtered
through a 0.22 mm membrane, and diluted with 3 volumes of
equilibration buffer (20 mM sodium phosphate, 300 mM NaCl,
10 mM imidazole, pH 7.4 (for rSmCD59.1) and pH 8.0 (for
rSmCD59.2). The recombinant proteins were then purified by metal
affinity chromatography using the A¨KTAprime system (GE
Healthcare) under native conditions. Briefly, the sample was loaded
onto a Ni2+-NTA column (5 mL bed volume) pre-equilibrated with
the same buffer. The column was washed with 20 bed volumes of the
equilibration buffer and then eluted with a 20–500 mM imidazole
linear gradient. Fractions encompassing the main peak were
characterized by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE). Eluted fractions containing the recombinant
protein in near pure form were pooled and submitted to extensive
dialysis in Phosphate Buffer Saline pH 7.4 (PBS). This sample was
analyzed by SDS-PAGE and stained with Schiff’s reagent (Sigma) for
detection of glycoproteins as per the manufacturer’s recommenda-
tions. Bovine Serum Albumin (BSA) (Bio-Rad) (non-glycosylated
protein) and rSmVAL4 (glycosylated protein) were used as controls
for the specificity of the reaction [45]. The rSmCD59.1 and
rSmCD59.2 proteins expressed in P. pastoris were glycosylated
(products between 14.4 kDa and 20.1 kDa), based on their staining
with Schiff’s reagent and increased size in SDS-PAGE (as can be
observed by the protein band shift in comparison to the rSmCD59.2
expressed in E. coli (Figure S1). Both recombinant proteins were used
in the hemolytic assay and to generate polyclonal antibodies in rats.
Expression of recombinant SmCD59.2 in Escherichia coli
The pAE-SmCD59.2 was transformed into E.coli BL21 (SI)
(Life Technologies) and the transformed cells were grown in
300 mL LB ON plus ampicillin (100 mg/mL) until they reached
an OD600 = 0.7, after which induction was performed by
addition of 300 mM sodium chloride (NaCl) for another 4 h at
30uC. Harvested cells resuspended in 30 mL of lysis buffer
(20 mM Tris pH 8.8, 150 mM NaCl) were lysed in a French
Press. The pelleted inclusion bodies obtained by centrifugation
at 20,0006 g for 30 min were washed twice with wash buffer
(lysis buffer, 2% Triton X-100, 2 M urea), and finally
resuspended in solubilization buffer (lysis buffer, 10 mM
imidazole, 8 M urea). The recombinant protein was refolded
from the inclusion bodies by diluting 200-fold into equilibration
buffer (solubilization buffer without urea). The recombinant
protein was then purified by metal-affinity chromatography
using the A¨KTAprime system under native conditions. Briefly,
the sample was loaded onto a Ni2+-NTA column pre-
equilibrated with equilibration buffer. The column was washed
with 10 bed volumes of the equilibration buffer and then eluted
with 10–500 mM imidazole linear gradient. The main peak was
pooled and the protein purity of fractions was assessed by SDS-
PAGE. Before its use the protein was dialyzed against PBS,
pH 7.4. This sample was used in the hemolytic assay and to
generate polyclonal antibodies in rats.
Polyclonal rat antiserum was produced against the preparations
of rSmCD59.1 (P. pastoris) and rSmCD59.2 (E. coli). Rodents were
inoculated three times subcutaneously, at 15-day intervals with
100 mg of protein mixed with TiterMax adjuvant (CytRx
Corporation; first dose) or PBS (in subsequent doses). Fifteen days
after the last inoculation, rodents were exsanguinated.
Schistosome protein extraction
Total protein extracts from eggs, miracidia, cercariae, 7 day-old
schistosomula and adult worms of S. mansoni were prepared as
previously described [41]. The tegument extract was obtained
using a freeze/thaw/vortex procedure [46].
Tegument surface membranes (Tsm) and tegument-extract
without-surface membranes (Twm) were obtained after a low
speed centrifugation (1006 g, 30 min) (adapted from [46]).
Additionally, soluble (Sol) and insoluble (Ins) fractions of stripped
worms after tegument removal were prepared as previously
described [47]. The protein extract concentrations were deter-
mined with a RC DC Protein Assay Kit (Bio-Rad, CA, USA).
Purified rSmCD59.1 or rSmCD59.2 (100 ng) and different
parasite extracts (20 mg) were subjected to SDS-PAGE. The gel
was electroblotted onto PVDF membrane, which was blocked with
0.02 M Tris (pH 7.5) and 0.3% Tween 20 containing 5% dry milk
for 16 h at 4uC. The membranes were incubated in 1:2,000 or
1:5,000 dilution of anti-rSmCD59.1 and anti-rCD59.2 primary
antibody, respectively in blocking buffer plus 150 mM NaCl for
3 h at room temperature. After three washes using 150 mL of
10 mM Tris (pH 7.5), the membranes were incubated in a 1:5,000
dilution with secondary goat anti-rat IgG conjugated to horserad-
ish peroxidase (Sigma) for 1 h, followed by another three washes
using the same buffer. Antibody reactivity was developed with
ECL reagent (GE Healthcare) according to the manufacturer’s
instructions and imaged using Hyperfilm or Image Quant LAS
(GE Healthcare).
Indirect immunofluorescence and confocal microscopy
Immunocytochemistry on whole adult worms followed a
previously described protocol [48]. Briefly, adult worms were
fixed in 4% paraformaldehyde for 4 h, washed in PBS (0.1 M,
pH 7.4) for 1 h and then transferred to a fresh fixative for another
3 h. After permeabilization with 1% Triton X-100, 0.1% SDS,
10% (heat-inactivated) rabbit serum, 0.1% NaN3 in PBS overnight
at 4uC, the worms were incubated with primary antibody, diluted
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1:200, for 96 h at 4uC. After extensive washes, the worms were
incubated for 48 h with 100 ng/mL of Phalloidin-rhodamine
(Molecular Probes, Life Technologies), to stain the musculature of
the parasite, and with Alexa Fluor 488-labeled rabbit-anti-rat
antibody (1:200, Molecular Probes, USA) in PBS containing 0.1%
Triton X-100, 1% BSA, 0.1% NaN3 and 10% rabbit serum at
4uC. After several rinses, the worms were visualized with a LSM
510 Meta confocal microscope (Zeiss), attached to a Zeiss Axiovert
100 microscope.
For cryosection analysis, perfused adult worms were embedded
in OCT medium (Tissue-Tek, Sakura) in a pre-cooled beaker of
isopentene, frozen in liquid N2. Eight-micrometer cryostat adult
worm sections were obtained and adhered to silanized glass slides
(DakoCytomation, USA) and fixed in acetone for 30 min at
220uC before blocking with 16 PBS, 10% Naive rabbit serum
and 0.1% Tween 20 (PNT) overnight at 4uC. They were then
incubated with anti-rSmCD59.1 and anti-rSmCD59.2 anti-serum
diluted 1:100 in PNT for 4 h at room temperature. After five
washes with PBS 0.1% Tween 20, pH 7.4 (PBS-T), an Alexa Fluor
488 conjugated anti-rat IgG (1:200) (Life Technologies) and
20 mM DAPI (49, 6-diamidino-2-phenylindole dihydrochloride,
Molecular Probes) to visualize nuclei were added to the PNT
solution and samples were incubated for 1 h at room temperature.
Sections were washed five times, and then mounted in Fluorescent
Mounting Medium (DakoCytomation). Rat pre-immune sera were
used as negative control. Images were acquired as described
above.
Hemolytic assays
Briefly, to evaluate Alternative Pathway activity, washed rabbit
erythrocytes (ERs) were diluted in AP-CFTD (144 mM NaCl,
0.96 mM sodium barbital, 2.48 mM barbituric acid, 1.4 mM
MgCl2, 10 mM EGTA) and then added to Normal Human Serum
(NHS) (serial dilutions 1:4 to 1:256). After incubation at 37uC for
30 min, VBS2EDTA (144 mM NaCl, 0.96 mM sodium barbital,
2.48 mM barbituric acid, 20 mM EDTA) was added to stop lysis.
After centrifugation (0.86 g for 10 min at 4uC) the supernatant
absorbance was measured at 405 nm and percentage hemolysis
was calculated using ERs lysed by water as the 100% reference.
The serum volume that produced 50% lysis of ERs was
determined and used in the inhibition assays [49,50]. To evaluate
the hemolytic activity mediated by the Classical Pathway, washed
antibody-sensitized sheep erythrocytes (EAs) were diluted in
VBS++ (144 mM NaCl, 0.96 mM sodium barbital, 2.48 mM
barbituric acid, 0.83 mM MgCl2, 0.25 mM CaCl2) and were
added to NHS (serial dilutions 1:20 to 1:500). After incubation at
37uC for 30 min, samples were centrifuged (0.86 g for 10 min at
4uC) and the supernatant absorbance at 405 nm was measured.
The hemolysis percentage (relative to EAs suspension completely
lysed by water) was calculated. The volume of serum necessary to
promote 50% lysis of EAs was determined and used in the
inhibition assays [50].
Inhibition assays were performed to evaluate if the proteins
rSmCD59.1 and rSmCD59.2 (produced in P. pastoris and in E. coli)
were able to protect ERs from the lysis triggered by the Alternative
Pathway, or EAs from the lysis by the Classical Complement
Pathway. BSA (Sigma-Aldrich) was used as a negative control.
Different amounts of the proteins (0, 2, 5 and 10 mg for the
Alternative Pathway, and 0, 1, 2 and 4 mg for the Classical
Pathway) were pre-incubated with NHS (corresponding to 50%
lysis) for 20 min at 37uC. Washed ERs (3.56106) or EAs (6.76104)
were incubated with treated NHS for 30 min at 37uC. After
centrifugation (0.86 g for 10 min at 4uC), the supernatant
absorbance at 405 nm was measured and % hemolysis was
calculated.
SmCD59.1 and SmCD59.2 transfected CHO cells
CHO cells were obtained from American Type Culture
Collection (Manassas, VA) and cultured as monolayers in
100 mm cell culture dishes using DMEM/F12 medium (Life
Technologies) supplemented with 10% fetal calf serum (FCS),
2 mM L-glutamine, 100 units/mL penicillin and 50 mg/mL
streptomycin sulfate. Cells were maintained at 37uC and 5%
CO2 and reseeded twice a week using 0.05% trypsin.
The full size SmCD59.1 and SmCD59.2 coding regions,
including the putative domains for the signal peptide and GPI
anchor, respectively, were codon optimized for human and
hamster codon preferences, synthesized (Genscript USA Inc.,
Piscataway, NJ) (Table S1) and cloned into pcDNA-3.1(+) via
BamHI/XhoI restriction sites. A full length hCD59 cDNA
obtained from Open Biosystems/Thermo Scientific, AL was
sub-cloned into pcDNA to serve as a positive control for protein
expression and complement inhibitory studies in CHO cells.
The recombinant plasmids were transiently introduced into 70–
80% confluent CHO cells cultured in 6 well-plates using the
polymer-based DNA transfection agent jetPEI (Polyplus,
France) according to manufacturer’s instructions. Transfected
cells were cultured for an additional 48 h before harvesting.
CHO cells transfected with empty vector were included as
negative control.
CHO cells transiently transfected with SmCD59.1 and
SmCD59.2 were tested for membrane protein expression. Cells
expressing hCD59, or containing empty pcDNA, were included
as positive and negative controls, respectively. For fluorescent
microscopy and flow cytometry analysis, live cells were washed
twice with PBS without CaCl2 and MgCl2 and detached from
the plate with a non-enzymatic cell dissociation solution
(Sigma). Cells were washed once with DMEM/F12 containing
0.2% BSA (DMEM-BSA) by centrifugation at 1006 g for 5 min
and resuspended to 106 cells/mL in the same medium. Cells
were incubated for 30 min at room temperature with the
respective primary antibodies, i.e. CHO-SmCD59.1 with rat
polyclonal serum anti-rSmCD59.1 at 1:500 dilution; CHO-
SmCD59.2 with an anti-rSmCD59.2 at 1:500 and CHO-
hCD59 with a rat monoclonal antibody anti-hCD59 at 1:2,000.
After 2 washes with DMEM-BSA, cells were incubated with a
secondary FITC-labeled goat anti-rat IgG (Invitrogen, Life
Technologies). Cells were immediately visualized under an
inverted fluorescent microscope and positive cells were quan-
tified by flow cytometry after subtracting fluorescent back-
ground from cells transfected with empty vector. For analysis by
Western blot, detached cells were washed twice with PBS and
membrane extract was prepared using the ProteoExtract Native
Membrane Protein Extraction Kit (EMD Millipore, Billerica,
MA), following manufacturer’s instructions. The membrane
fractions were incubated with each corresponding primary
antibody followed by HRP-labeled goat anti-rat IgG (Invitro-
gen) and developed using the ECL Western Blot Developing
System.
To confirm that SmCD59 is GPI-anchored in transfected
CHO cells, we followed previously described methodology for
hCD59 [51]. Briefly, transfected cells were removed from
culture plate wells, washed in Hank’s Balanced Salt Solution
(HBSS) and exposed to 1 Unit/mL of PiPL-C (Sigma) in HBSS
or kept in buffer only as control. After incubation for 1 h at
37uC, cells were stained with the antibody anti-rSmCD59.1 and
the percentage of fluorescent cells was quantified and compared
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with the control sample not treated with PiPL-C using flow
cytometry.
Complement resistance of CHO cells expressing
SmCD59.1 and SmCD59.2
CHO cells expressing SmCD59.1 and SmCD59.2 were tested
in a complement mediated cell damage assay to determine
whether these proteins have complement regulatory activity.
This approach was performed according to previously reported
methodologies described for hCD59 [51,52], with some
modifications. Briefly, CHO cells transiently transfected with
SmCD59.1, SmCD59.2, hCD59 and empty vector were
detached from 6-well culture plates as described in the previous
section, washed and incubated with 5% rabbit anti-CHO
membrane serum in DMEM-BSA for 30 min at room temper-
ature, washed twice with DMEM-BSA and incubated with 10%
NHS (Complement Technology, USA) in DMEM-BSA as
source of human complement factors. Following 1 h sample
incubation at 37uC, cell viability was determined by adding the
vital dye propidium iodide at 5 mg/mL and the population of
live cells (not stained by propidium iodide) were identified by
flow cytometry. Samples with NHS heated at 56uC for 30 min
to inactivate complement were used to measure background cell
mortality.
Suppression of SmCD59.1 and SmCD59.2 gene
expression by RNAi
Gene-specific siRNAs were commercially synthesized (Integrat-
ed DNA Technologies, Inc., IA) and used to induce gene
expression knockdown of SmCD59.1 and SmCD59.2, respective-
ly, by electroporation as described [53]. The DNA sequence for
SmCD59.1 siRNA is 59-CTACAAGTGACTAGTCGTAGT-
TGTG-39, spanning coding DNA positions 193–217. SmCD59.2
siRNA sequence is 59-GGTAAAGCTGGCTTAGTAACT-
GAAT-39 spanning coding DNA positions 241–265. The negative
control siRNA was acquired from IDT and has been previously
tested by our own group [53]. Briefly, freshly transformed
schistosomula were placed into electroporation buffer (Bio Rad,
CA) containing a mixture of SmCD59.1 and SmCD59.2 siRNAs
at 5.6 mM each or control siRNA (11.2 mM) or no siRNA.
Parasites were immediately electroporated and then cultured for 5
days in DMEM/F12 medium containing 10% FCS at 37uC, in an
atmosphere of 5% CO2. Reduction in target transcript levels was
measured by qRT-PCR relative to transcript levels in parasites
Figure 1. ClustalX multiple sequence alignment of the mature protein sequence (excluding the signal peptide) of TFPDs from
platyhelminthes, CD59 and Ly6. The regions with high identity and similarity between sequences are shown as black and gray columns,
according to the ClustalX algorithm. Arrows indicate highly conserved Cysteines and Asparagines with a C and an N, respectively. Dashed lines
represent pairs of cysteine residues forming disulfide bonds determined from Hs-CD59 (red) and predicted for SmCD59.2 (black). Only for SmCD59
sequences, potential sites for N-glycosylation are shown in blue with asparagine (N) in red, and potential sites for GPI anchor are shown in yellow.
Human CD59 active sites are shaded in red. The sequences abbreviation are: Schistosoma mansoni (SmCD59.1-7), Schistosoma japonicum (Sj1, Sj2.3,
Sj3, Sj4.1, Sj6), Schistosoma hematobium (Sh1-3 and Sh5-7), Clonorchis sinensis (Cs-757, Cs-8328, Cs-8627), Opisthorchis viverrini (Ov-8524, Ov-3995 and
Ov-6738), Fasciola hepatica (Fh-6273), Fasciola gigantica (Fg-25430 and Fg-15245), Schmidtea mediterranea (Smed), Equus caballus (Ec-Ly6), Pongo
abelii (Pa-Ly6 and Pa-CD59), Macaca mulatta (Mam-Ly6), Mus musculus (Mm-Ly6 and Mm-CD59), Monodelphis domestica (Md-Ly6), Ornithorhynchus
anatinus (Oa-Ly6), Homo sapiens (Hs-Ly6 and Hs-CD59), Saimiriine herpesvirus (Sah-CD59), Rattus norvegicus (Rn-CD59) (the accession numbers are
listed in the Table S2).
doi:10.1371/journal.pntd.0002482.g001
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treated with control irrelevant siRNA (100% gene expression).
Decrease in SmCD59.1 and SmCD59.2 protein levels was
measured in whole parasite lysates by Western blots. Schistosom-
ula lysates were prepared by adding 80 mL of RIPA buffer
containing a cocktail of protease inhibitors followed by incubation
on ice for 1 h. The protein content in each extract was estimated
using the BCA Protein Assay Kit (Pierce, IL) according to the
manufacturer’s instructions. Soluble protein (800 ng) was subject-
ed to SDS-PAGE, blotted onto PVDF membrane and blocked
with PBS containing 0.1% Tween 20 and 5% milk for 1 h at room
temperature. The membrane was then probed overnight at 4uC
with anti-rSmCD59.1 or anti-rSmCD59.2 immune rat serum at
1:500 dilution or rabbit antibody directed against the schistosome
protein aquaporin (SmAQP) as loading control at 1:250 dilution.
Bound primary antibodies were detected by appropriate secondary
antibodies conjugated to horseradish peroxidase and exposure to
Table 1. Molecular characteristics of Schistosoma mansoni CD59-like proteins.
Namea
S. mansoni
v5 IDb
pI/Mwc
(kDa)
Orthologd
Organism (% id) Primary structure analysis
e
Locationf
Expression
Signal
Peptide Domain
GPI
anchor
SmCD59.1 Smp_019350 8.11/11.0 Ly-6 Sarcophilus harrisii (34%) x uPAR/Ly6/CD59/snake toxin x Tegument1 q
Day 3 Sch2
SmCD59.2 Smp_105220 8.33/12.1 Ly-6D Macaca mulatta (33%) x uPAR/Ly6/CD59/snake toxin x** Tegument1 q
Day 3 Sch2, 3
SmCD59.3 Smp_081900.2 8.47/11.4 CD59 Myotis davidii (30%) x x** q Day 3 Sch2
SmCD59.4 Smp_166340 8.65/11.5 Ly-6 Desmodus rotundus (34%) x x** Tegument4 q
Day 3 Sch2
SmCD59.5 Smp_081920 8.66/11.6 CD59 Myotis davidii (29%) x uPAR/Ly6/CD59/snake toxin x** Tegument4 q
Day 3 Sch2
SmCD59.6 Smp_166350 9.00/11.5 CD59 Canis lupus familiaris (27%) x uPAR/Ly6/CD59/snake toxin x**
SmCD59.7 Smp_125250 8.95/11.4 Ly-6D Saimiri boliviensis (24%) x* x**
aProposed gene names (accession numbers of cloned cDNAs).
bSchisto GeneDB version 5 systematic ID.
cMolecular weight and isoelectric point.
dBLASTx analysis for identification of the closest ortholog in GeneBank; ortholog protein, organism, identity.
eSMART predicts the presence of domains in the protein sequence.
fLocation of the protein in proteomic studies and up regulated stages by microarray analysis;
(1)Castro-Borges et al., 2011;
(2)Parker-Manuel et al., 2011;
(3)Farias et al., 2010;
(4)Wilson, 2012.
*Signal peptide prediction with SignalP 4.1 server (D-scores above 0.4 but below 0.5).
**GPI Prediction Server (Version 3.0) bellows the cut-off.
doi:10.1371/journal.pntd.0002482.t001
Figure 2. Homologymodeling of SmCD59.2. Ribbon display, side view (A) and top view (B). The models were generated with Modeller 5.1 using
3-D structure of human CD59 as a template (2UWR). The quality of the model was assessed with Procheck. Disulfide bridges are visualized as magenta
sticks, and the three finger-shaped backbone is visualized as projections emerging from the disulfide bridges.
doi:10.1371/journal.pntd.0002482.g002
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ECL substrate. The same membrane was probed three times to
detect SmCD59.1, SmCD59.2 and the control protein, SmAQP.
For each re-use, the membrane was stripped with Western Blot
Stripping Buffer (Thermo Scientific, IL) following manufacturer’s
instructions to remove bound antibody.
Complement killing assay of SmCD59.1 and SmCD59.2
suppressed schistosomula
SmCD59.1 and SmCD59.2 suppressed schistosomula were
tested in a complement killing assay modified from Deng et al.
[27]. Briefly, 200 control and siRNA-suppressed parasites
cultured for 5 days were washed in DMEM/F12 and incubated
for 30 min at 37uC with serum (1:4 dilution) from rats infected
twice with cercariae (IRS) or with naive rat serum (NRS), both
heat-inactivated. Parasites were washed with medium and
incubated overnight at 37uC with undiluted NHS as a source
of complement. Suppressed and control schistosomula were also
tested for complement killing in the absence of rat serum. After
18–24 h, schistosomula were exposed to 1 mg/mL of DNA
binding stain Hoechst 33258 dye for 5 min and examined with
an inverted fluorescent microscope to count the number of dead
fluorescent parasites under ultraviolet light (352 excitation/455
emission) [54]. Dye uptake only occurs if there is complement
induced-tegumental damage. Samples were run in duplicates in
three independent experiments. Percent net mortality was
calculated by subtracting background mortality of parasites
treated with heat-inactivated NHS. The same complement killing
assay protocol was used to measure mortality of freshly
transformed schistosomula cultured for 3 h in DMEM/F12 plus
10% FCS.
Results
Sequence and in silico analyses
BlastP comparisons of SmCD59.1 and SmCD59.2 sequences to
GenBank revealed low similarity with orthologs of CD59 proteins
belonging to the uPAR/Ly6/CD59/snake toxin-receptor super-
family (E-value, ranging from 3610210–461024). Because this is
the first article to deal specifically with this schistosome gene
family, herein we propose numbering of these genes as shown on
Table 1. In addition to the six previously reported S. mansoni
sequences, SmCD59.1-6, it was possible to identify a new S.
mansoni member (SmCD59.7 – Sm_125250) (Table 1), which
displays a slightly different distribution of Cys 10 (Figure 1).
Furthermore, nine sequences from S. japonicum and six from S.
hematobium could be identified, and all branched together with the
S. mansoni members representing possible orthologs (Figure S2). In
spite of the low bootstrap value, all these sequences did not branch
together with mammalian Ly6 or CD59 sequences. Additionally,
searching other databases, 13 non-characterized proteins from
other Platyhelminthes species were identified (E-value, ranging
from 9610219–261027). Noteworthy, was the identification of a
member in the turbellarian S. mediterranea (Figure S2).
Analyses of the primary sequences revealed the presence of ten
conserved cysteine residues following the same pattern of distribu-
tion in Platyhelminthes (Figure 1). A very intrinsic characteristic of
the TFPD fold is the presence of at least four conserved cystines
among all the different classes of proteins having this domain [30].
Nonetheless, this pattern differs from the CD59s of mammals in the
3rd and 4th cysteines, which are separated by a larger stretch of
amino acids in the Platyhelminthes sequences and are located at a
distance of exactly two amino acids from their closest cysteines (2nd
and 5th Cys). These distances (from the 2nd to the 3rd and from the
4th to the 5th Cys) in mammals are more variable. However, the
most important difference of these molecules when compared to
human CD59, is that they do not have the conserved amino acid
residues (D24, W40, R53 and E56 in hCD59) involved in
complement recognition [30,55], as well as the ‘‘hydrophobic
groove’’ (C39, W40 and L54 in hCD59), highly conserved in all
CD59s [55]. The sequence belonging to Herpesvirus Saimiri
Protein (Sah-CD59) was included as a homolog from human CD59.
Similarly, a glycine adjacent to the sixth cysteine (characteristic of
toxins) is not present in the sequences [33] (Figure 1).
Homology modeling
In order to explicitly visualize the putative domain features and
also provide insight into its folding, 3D-modeling of SmCD59.2
(Smp_105220) was performed using human CD59 as a template
(2UWR) (Figure 2). Despite the low similarity between the two
sequences (,37%), it was possible to align them in order to
Figure 3. Relative expression levels in different SmCD59 isoforms. Relative gene expression levels for each homologue was determined by
qRT-PCR and represented as mean (+ SD) from technical triplicates. The developmental stages examined were cercariae, schistosomula (11-day
cultured), and adult pairs (6-week old).
doi:10.1371/journal.pntd.0002482.g003
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perform the modeling. Out of the 124 residues, 73 of them were
modeled (beginning at V25, which becomes V1 in the mature
protein, and ending at A97, becoming A73). The last 27 residues
at the C-terminal remained out of the model, since they did not
show any similarity to 2UWR (Figure 1). RMSD was of 1.24 A˚
between template and models in the common core (36 alpha-
carbon atoms).
In this model, the finger-shaped backbone is present within the
structure, emerging from a hydrophobic palm, clearly seen in
Figure 2A. Additionally, the four conserved cystines can be
observed (Figure 2B) and would be formed by the following pairs:
Cys3-Cys27, Cys24-Cys45, Cys49-Cys65 and Cys66-Cys71.
There are another two conserved cysteines in the Schistosoma spp.
(Cys6 and Cys9 in SmCD59.2) that may not form a disulfide
bridge. However, the possibility of a fifth cystine formed by these
two cysteines cannot be ruled out, since the model generated is not
necessarily a real portrait of the native molecule’s fold. All these
spatial conformations are possible since the TFPD signature is
present in the sequence (Figure 1). The geometry of the final
refined model was evaluated with a Ramachandran plot, which
showed that 97% of the amino acid residues were positioned in the
‘‘allowed’’ regions (data not shown).
Most of the SmCD59 genes are differentially expressed in
the transition from cercaria to schistosomulum and adult
worms
In order to establish the level of expression in different parasite
stages, including cercariae, in vitro cultured 7-day old schistosom-
ula, adult worms, eggs and miracidia, qRT-PCR was performed
using SYBR Green (Life Technologies). Gene expression fold
changes of each SmCD59 were calculated relative to the less
expressed stage after normalization to the alpha-tubulin house-
keeping gene. The results show that the SmCD59 genes, with the
exception of SmCD59.6, display increased gene expression in the
schistosomulum and adult worm stages (Figure S3).
To evaluate the relative expression levels between the different
SmCD59 isoforms, qRT-PCR was performed using the Taqman
system on three stages, the free living infective stage (cercaria), in
vitro cultured 11-day old schistosomula and adult worms.
SmCD59.1, SmCD59.3 and SmCD59.4 showed the highest levels
of expression with higher expression in the schistosomula and
adult stages, while SmCD59.2, SmCD59.5 and SmCD59.7
showed intermediate levels of expression and SmCD59.6 was
found at very low levels (Figure 3).
SmCD59 protein expression profile across the parasite
life cycle stages
Samples prepared from cercariae, schistosomula, adult male
and female worms, eggs and miracidia stages from S. mansoni, and
tegument isolated by the freeze/thaw method, were all separated
by 15% SDS-PAGE. Immunoblotting was performed using mouse
anti-rSmCD59.1 and anti-rSmCD59.2 antisera. The protein
expression profile of SmCD59.1 generally correlated with the
Real Time RT-PCR data, revealing low expression in miracidia
and cercariae, increasing in schistosomula and adult worms
(Figure 4A). A lower intensity band of higher molecular mass may
be attributed to some cross reactivity with other SmCD59
members (possibly glycosylated) (Figure 4A), as suggested by the
in silico predicted N-glycosylation sites (Figure 1). In the case of
SmCD59.2, a similar expression profile with higher levels in
schistosomula was observed (Figure 4B).
Notably, after the separation of the tegument from the worm
body, the SmCD59.1 protein was detected only in the insoluble
fraction of stripped worms (Figure 4C). We cannot rule out the
presence of this protein in the tegument fraction; however, this
data suggested that the protein is much more abundant in
denuded worms than in the tegument. The SmCD59.2 protein
was found to be more abundant in stripped worms, with similar
proportions in the soluble and insoluble fractions (Figure 4D).
Furthermore, analysis of the tegument surface membrane fraction
revealed that the small amount of protein present in the tegument
is membrane associated, with no protein detected in the soluble
supernatant (soluble syncytial proteins) (Figure 4D).
SmCD59.1 and SmCD59.2 present a ubiquitous
localization in adult worms of S. mansoni
Immunolocalization studies on whole adult worms using rat
serum raised against rSmCD59.1 and rSmCD59.2 revealed that
both proteins were expressed on the surface of S. mansoni adult
Figure 4. Immunoblotting of protein extracts from S. mansoni stages using anti-rSmCD59.1 or anti-rSmCD59.2 polyclonal
antibodies. Protein extracts (20 mg) from different S. mansoni stages: EGG (eggs), MIR (miracidia), CER (cercariae), SCH (in vitro 7-day-old
schistosomula), = (male adult worm), R (female adult worm) and P (positive control, 100 ng of rSmCD59.1) were analyzed using (A) anti-rSmCD59.1
antiserum; or (B) anti-rSmCD59.2 antiserum, P (positive control, 100 ng of rSmCD59.2 expressed in E. coli). Extracts of stripped worms (Strip) and
Tegument (Teg) of adult worms were probed with (C) anti-rSmCD59.1 or (D) anti-rSmCD59.2 antisera. Insoluble (Ins) and soluble (Sol) protein extracts
of stripped worms; (Tsm) enriched tegument surface membranes fraction; (Twm) tegument extract without surface membranes. Positions of
molecular mass standard are indicated.
doi:10.1371/journal.pntd.0002482.g004
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Figure 5. Fluorescence confocal microscopy images showing immunolocalization of SmCD59.1 and SmCD59.2 in whole mount and
in transverse sections of S. mansoni adult worms. (A and B) Confocal projections of SmCD59.1 and SmCD59.2 protein in the tegument of whole
mount adult male worms. (D and E) Fluorescence detection of SmCD59.1 and SmCD59.2 in transverse sections of S. mansoni adult worms. (C and F)
Negative control, serum from naı¨ve rat. Secondary antibody coupled to Alexa 488 (green) was used for SmCD59 localization. DAPI (blue) was used for
nucleus localization (E and F) and Rhodamine Phalloidin (red) was used for actin localization (A, B and C). Arrows – tegument tubercules; M – male; F –
female; p – parenchyma; mc – muscle cells.
doi:10.1371/journal.pntd.0002482.g005
Figure 6. Evaluation of the ability of SmCD59.1 and SmCD59.2 to modulate complement activity. Hemolytic assays were performed
after incubating normal human serum (NHS) with different amounts of SmCD59.1 (produced in P. pastoris), SmCD59.2 (produced in P. pastoris or E.
coli), or BSA (negative control). (A) Treated NHS was then incubated with rabbit erythrocytes (Alternative Pathway) or (B) antibody-sensitized sheep
erythrocytes (Classical Pathway). The percentage of hemolysis was calculated in comparison with erythrocytes suspensions completely lysed with
water (100% lysis). The volume of NHS used in these assays corresponds to the amount that promotes 50% lysis of erythrocytes. Each column
represents the mean of three independent experiments 6 SD.
doi:10.1371/journal.pntd.0002482.g006
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male worms, as shown by the green staining apparent around and
over their dorsal tubercules (Figure 5A and B). However, analysis
of adult worm sections revealed that SmCD59.1 protein is also
expressed at significant levels in the parenchyma cells of male and
female adult worms (Figure 5D), while SmCD59.2 protein shows
even a broader localization, including muscle cells of male and
female adult worms (Figure 5E).
Investigation of the inhibition of complement-mediated
hemolysis by rSmCD59.1 and rSmCD59.2 proteins
In order to investigate the involvement of SmCD59 isoforms in
the inhibition of the complement cascade, NHS was pre-incubated
with various amounts of rSmCD59.1 and rSmCD59.2 proteins,
and then added to rabbit erythrocytes (Alternative Pathway) or
antibody-sensitized sheep erythrocytes (Classical Pathway). Our
data revealed that the rSmCD59 isoforms and the negative control
BSA did not inhibit hemolysis triggered by the Alternative or
Classical Complement Pathways (Figure 6). The NHS used in
these assays promoted 50% erythrocyte lysis and addition of the
recombinant schistosome proteins or BSA did not alter this
percentage. These results therefore suggest that the rSmCD59
isoforms are not involved in the inhibition of complement
deposition by the Classical or Alternative Pathways.
Evaluation of complement resistance of CHO cells
expressing SmCD59.1 and SmCD59.2
It has been shown that the membrane form of hCD59 (GPI-
anchored) is about 5 to 10 times more active at inhibiting the
complement system as compared to the soluble form lacking the
GPI anchor [56,57]. Thus, CHO cells were transfected with the
codon optimized full-length cDNA of SmCD59.1 (CHO-
SmCD59.1) and SmCD59.2 (CHO-SmCD59.2) to measure
complement resistance of cells expressing these membrane-
anchored proteins. Cells transfected with hCD59 (CHO-hCD59)
and empty vector (CHO-pcDNA) were included as positive and
negative controls, respectively.
Expression of SmCD59.1 in the CHO cell surface was
demonstrated by positive staining of the membrane of live cells
with an anti-rSmCD59.1 antibody. Flow cytometer analyses
confirmed expression of SmCD59.1 in about 20% of the transfected
cells (Figure S4A). Similar results were obtained with hCD59
(Figure S4B). Expression of SmCD59.2 in the cell membranes was
detected by Western blot of a membrane preparation of transfected
cells (anti-rSmCD59.2 rat serum did not react with endogenous
CD59 protein in live CHO cells – data not shown). To confirm that
SmCD59.1 is GPI-anchored, transfected CHO cells were treated
with PiPL-C, labeled with anti- rSmCD59.1 antibody and analyzed
by flow cytometry. As shown in Figure S4C (top panels), there was a
pronounced reduction in antibody labeling anti-rSmCD59.1 after
treatment with PiPL-C (6.8%) as compared to untreated cells
(25.8%). Results were similar for CHO-hCD59 cells included as
positive control (bottom panels).
CHO-SmCD59.1 and CHO-SmCD59.2 were tested for
complement resistance when exposed to antibodies reactive to
CHO membrane proteins and to complement from NHS.
Background cell mortality was monitored by including samples
treated with heat-inactivated complement (iNHS). Complement-
treated cells were analyzed by flow cytometry to quantify the live
cell population, i.e. cells of reduced fluorescence that are not
stained by propidium iodide (Figure 7). The number of viable cells
in the CHO-hCD59 sample was considerably higher than the
number of live cells in the CHO-pcDNA sample after addition of
NHS (Figure 7A, first peak in left panel). T-test analysis of three
independent experiments (Figure 7D) showed that CHO-hCD59
cells were significantly more resistant to complement (73.4%69.1)
than CHO-pcDNA cells (37.8%69%) (p,0.05). When cells were
treated with iNHS, the number of live cells in both samples was
nearly identical and close to 95% (Figure 7A, first peak in right
panel and Figure 7D), confirming the complement inhibitory
Figure 7. Complement resistance of CHO cells expressing
SmCD59.1, SmCD59.2 and hCD59 (positive control). Viable cells
were quantified by flow cytometry following exposure to anti-CHO
antibodies and normal human serum (NHS) or heat-inactivated serum
(iNHS). Black histograms are CHO cells transfected with hCD59 (A),
SmCD59.1 (B) or SmCD59.2 (C), respectively. Red histograms are control
cells transfected with empty pcDNA vector (A, B and C). The first peak in
both black and red histograms represents viable cells and the second
peak represents dead cells stained by propidium iodide (PI). (D) Cell
viability of CHO cells transfected with hCD59 or pcDNA treated with
anti-CHO antibodies and NHS or iNHS in three independent exper-
iments (mean 6 SD). P values are indicated.
doi:10.1371/journal.pntd.0002482.g007
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activity of hCD59 in the transfected cells. The same cell survival
analysis was performed on CHO-SmCD59.1 and CHO-
SmCD59.2 samples, but there was no difference in cell viability
in both samples compared to CHO-pcDNA sample after exposure
to NHS (Figure 7B and 7C respectively). These results strongly
indicate that SmCD59.1 and SmCD59.2 are not complement
inhibitory proteins.
Effect of SmCD59.1 and SmCD59.2 gene suppression on
complement killing of schistosomula
To further assess whether SmCD59.1 and SmCD59.2 protect
schistosomes from the complement attack, freshly transformed
schistosomula were treated with a mixture of SmCD59.1 and
SmCD59.2 specific siRNAs and tested for complement susceptibil-
ity 5 days later. Transcript levels measured by qRT-PCR were
about 60% lower in SmCD59-suppressed parasites than in control
parasites (Figure 8A). Schistosomula were suppressed immediately
after cercarial transformation because SmCD59 mRNA levels are
undetectable by qRT-PCR at that early time point after which
expression increases significantly (data not shown). This approach
was expected to ensure that SmCD59 gene knockdown would
substantially inhibit protein production in siRNA-treated parasites,
while control parasites would have abundant protein levels. Indeed,
Western blot analysis in Figure 8B confirmed dramatic reduction of
SmCD59.1 (top panel) and SmCD59.2 (middle panel) proteins in
siRNA-suppressed parasites compared to lysates of control para-
sites. In the bottom panel, the SmAQP control protein was detected
in all lysates, demonstrating that comparable levels of protein were
present in each lane. The significant decrease of protein levels in
siRNA-suppressed schistosomula did not enhance in vitro parasite
killing by human complement beyond 20%, even in the presence of
immune serum when compared to the control groups in three
independent experiments (Figure 8C). Finally, data in figure 8D was
obtained to validate the complement assay and to confirm previous
results [3,4,7] in which, contrary to older schistosomula, 3 h-
cultured parasites are more susceptible to complement killing,
particularly when the killing is antibody mediated. Thus, our results
indicate that SmCD59.1 and SmCD59.2 are not complement
regulatory proteins in schistosomes.
Discussion
Early analysis of the S. mansoni sequences, SmCD59.1 and
SmCD59.2, revealed similarity to human CD59 [13,28,29]. In the
present report, we have described members of the TFPD family in
Figure 8. SmCD59.1 and SmCD59.2 gene expression knockdown and complement mediated killing assay of suppressed parasites.
(A) Relative SmCD59.1 and SmCD59.2 gene expression (mean 6 SE) in schistosomula 5 days after treatment with SmCD59 siRNAs or control siRNA
(control) or not treated parasites (none). ‘‘SmCD59.1+2’’ indicates parasites treated with a mixture of equal molar amounts of SmCD59.1 and
SmCD59.2 siRNAs. (B) Protein levels in SmCD59-suppressed and control schistosomula groups as described in (A). Western blot results are shown for
SmCD59.1 (top panel), SmCD59.2 (middle panel) and the S. mansoni aquaporin (SmAQP) as a loading control (bottom panel). (C) The parasites were
treated with immune rat serum (IRS), normal rat serum (NRS), or kept in medium only and then treated with normal human serum (NHS) as source of
complement. Percent net mortality of schistosomula is shown and was determined by background mortality subtraction of parasites treated with
heat-inactivated NHS. Results shown are mean 6 SD of duplicate samples in three independent experiments. (D) Freshly transformed schistosomula
(3 h in culture) were included as a positive control in the complement mediated killing assay.
doi:10.1371/journal.pntd.0002482.g008
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Platyhelminthes and compared their structure and folding to the
human CD59 protein [58]. This group of proteins contains the
TFPD fold, since the characteristic cysteines of this family are
present in their sequences. Despite the fact that the cysteines are
conserved, there are two important differences that are evident in
the alignment: i) the 3rd and 4th cysteines are in different positions
when aligned with their mammalian counterparts; nevertheless, all
the Platyhelminthes sequences maintain the two-amino acid
distance pattern between the 2nd/3rd and 4th/5th cysteines; ii)
the Platyhelminthes sequences lack the essential amino acids in the
active site required to block the formation of the MAC. However,
it is reasonable to expect that not all these features would be totally
conserved in trematodes and mammals, since these proteins may
have hypothetically evolved as complement inhibitors through
convergent evolution. For example, there is a fish homologue of
CD59, which was shown to have fish complement inhibitory
activity, but does not have many of the so-called ‘critical’ residues
conserved [59]. Furthermore, the presence of at least one CD59
member in the non-parasitic flatworm, S. mediterranea, suggests that
these proteins are also participating in aspects of non-parasitic
Platyhelminth biology. Moreover, it is at least intriguing how this
pattern remained conserved in inferior taxa, while in mammals it
seems to be more variable.
The transcription of most SmCD59 genes is up-regulated
following the transition from free-living cercaria to the parasitic
schistosomula stage; some of these genes continue to show
increasing transcription into the adult worm stage. These data
confirm previous microarray results showing up-regulation of
SmCD59.1-5 expression in 3-day old schistosomula in comparison
to germ-balls and cercariae [60]. Since SmCD59.1 and
SmCD59.2 are the only representatives of this family confirmed
to localize at the host-parasite interface by PiPL-C treatment, they
were chosen for additional characterization, including functional
studies. Western blot analysis of SmCD59.1 and SmCD59.2 at
different life cycle stages confirms that protein expression of these
genes also increases during the transition to the mammalian stage.
This coincides with the transition of the parasite from a
complement-sensitive state to one of resistance [5]. Confocal
microscopy immunolocalization studies using anti-rSmCD59.1
and anti-rSmCD59.2 antibodies confirmed previous data obtained
by PiPL-C shaving showing that the proteins were surface-exposed
on the tegument. On the other hand, it was clear that the proteins
were also present in considerable amounts inside the parasite,
which is in accord with the Western blot experiments on tegument
extracts and stripped worms. On the whole, these results further
support the concept that these proteins are probably involved in
aspects of non-parasitic schistosome biology.
Due to the sequence similarity, we also investigated whether
polyclonal antibodies directed to human CD59 (Abnova) could
recognize SmCD59.1 and SmCD59.2 and whether rat anti-
rSmC59.1 and anti-rSmCD59.2 polyclonal antibodies recognize
human CD59 (Abnova). However, no cross reactivity could be
observed in any of these studies (data not shown).
To demonstrate whether SmCD59.1 and SmCD59.2 are
functional homologues of human CD59, soluble rSmCD59
proteins produced in P. pastoris and E. coli were used to examine
their complement-inhibitory activity in an in vitro hemolytic assay
designed to favor the activation of the Alternative (rabbit
erythrocytes) or the Classical (antibody-sensitized sheep erythro-
cytes) Pathways, respectively. Soluble forms of CD59 lacking the
GPI-anchor domain have been expressed in mammalian cells,
insect cells and yeast and shown to have MAC-inhibitory activity
in vitro [57,61,62], indicating that glycosylation by Pichia pastoris
does not inhibit the protein function. However, in our study no
inhibition of erythrocyte lysis was observed when NHS was pre-
incubated with rSmCD59 proteins.
Membrane-targeted forms of CD59 have been shown to be
more potent in inhibiting complement than the soluble forms [54,59].
Thus, as an alternative approach, SmCD59.1 and 2 were expressed
as membrane proteins (complete coding region) in CHO cells
followed by treatment of transfected cells with human complement.
Membrane protein expression in CHO cells may also contribute to
produce rSmCD59 proteins as close to the native state as possible,
which is essential for functional studies. In addition, eukaryotic cells
transfected with complement regulatory proteins represent a more
physiologically relevant target for in vitro complement experiments as
compared to erythrocytes pre-treated with these proteins [63].
Despite our results showing proper localization of rSmCD59.1 and
rSmCD59.2 at the plasma membrane and proper GPI-anchorage of
rSmCD59.1, transfected CHO cells were not resistant to killing by
human complement. Taken together, these functional analyses
suggest that SmCD59.1 and SmCD59.2 do not possess inherent
complement inhibitory activities.
In a third attempt to investigate the potential of SmCD59.1 and 2
to protect schistosomes from complement attack, the parasites were
treated with target-specific siRNAs to induce gene expression
knockdown for both targets simultaneously. Despite successful
suppression of SmCD59.1 and 2 transcription and translation in
schistosomula, these parasites did not become more susceptible to
complement killing, by either the Alternative or the Classical
Pathways as compared to control parasites. We believe that these
results, together with the other complement assays and the sequence
and structural comparison, strongly support the conclusion that
SmCD59.1 and 2 do not have a complement regulatory function.
These schistosome CD59-like proteins probably have another
function in the parasite that is unrelated to complement evasion,
although it is quite likely that they are involved in some kind of
molecular interaction. This hypothesis is acceptable since TFPDs
commonly bind molecules, either as ligands (e.g. toxins) or
membrane-attached receptors, like CD59 or urokinase/plasmin-
ogen activator receptor, uPAR [33]. Gathering all the evidence,
we conclude that these CD59-like proteins do not have a
complement regulatory role in schistosomes. Thus, it would be
more appropriate to rename this class of proteins. However, since
several papers have been published on this gene family as
SmCD59 and the protein function is still unknown, it is reasonable
to change the family name only when their function is elucidated.
Further studies should focus on resolving the 3-D structure of the
proteins and deriving their function within the biological context
of the host/parasite relationship.
Supporting Information
Figure S1 Expression and purification of rSmCD59.1
and rSmCD59.2. (A) SDS–PAGE (15%) analysis of pooled
fractions of the recombinant proteins rSmCD59.1 and
rSmCD59.2 after purification through Ni+2-charged column
chromatography. Lane 1- rSmCD59.2 expressed in E. coli; lane
2 – rSmCD59.2 expressed in Pichia pastoris; lane 3 – rSmCD59.1
expressed in Pichia pastoris. (B) SDS-PAGE of rSmCD59.1 and
rSmCD59.2 stained with Schiff’s reagent to reveal the presence of
glycans, (C) the same gel was stained with Coomassie to show the
corresponding proteins. Positions of molecular mass standards
(kDa) are indicated, 20 mg of each protein was loaded in each lane,
rSmVAL4 was used as a positive glycosylated protein and BSA
was used as a negative control (non-glycosylated protein).
(PDF)
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Figure S2 Phylogenetic analysis performed with protein
sequences showing the relation between SmCD59 and
orthologs from other Platyhelminthes species. The
sequences abbreviation are: Schistosoma mansoni (SmCD59.1-7),
Schistosoma japonicum (Sj1, Sj2.1, Sj2.2, Sj2.3, Sj3, Sj4.1, Sj4.2, Sj4.3
and Sj6), Schistosoma hematobium (Sh1-3 and Sh5-7), Clonorchis sinensis
(Cs-757, Cs-8328, Cs-8627 and Cs-110927), Opisthorchis viverrini
(Ov-8524, Ov-3995, Ov-6738 and Ov-31372), Fasciola hepatica (Fh-
6273), Fasciola gigantica (Fg-25430, Fg-15245 and Fg-20490),
Schmidtea mediterranea (Smed), Equus caballus (Ec-Ly6), Pongo abelii
(Pa-Ly6 and Pa-CD59), Macaca mulatta (Mam-Ly6), Mus musculus
(Mm-Ly6 and Mm-CD59a), Monodelphis domestica (Md-Ly6),
Ornithorhynchus anatinus (Oa-Ly6), Homo sapiens (Hs-Ly6 and Hs-
CD59), Rattus norvegicus (Rn-CD59) (the accession numbers are
listed in the supplementary Table S2).
(TIF)
Figure S3 Analysis of gene expression of SmCD59.1,
SmCD59.2, SmCD59.3, SmCD59.4, SmCD59.5 and
SmCD59.6 genes in the egg, miracidia, cercariae,
schistosomula and adult stages. Total RNA from the
different life-stages were transcribed to cDNA and analyzed by
real-time RT-PCR to quantify the differences in expression levels
of the genes between stages. The alfa-tubulin house-keeping
control gene was used as normalizer and data were calculated
according to the relative 22DDCt method and shown as relative
mRNA expression in relation to the stage with less expression. The
data are the means (+) maximum expression variation of triplicates
from the same biological sample. ND – gene expression not
detected.
(PDF)
Figure S4 Flow cytometer and fluorescent microscopy
analysis of transiently transfected CHO cells for surface
expression of SmCD59.1. (A) Live cells were stained with a rat
polyclonal serum anti-rSmCD59.1 followed by FITC-conjugated
goat anti-rat IgG. SmCD59.1 transfected cells (red histogram in
left panel) were 18.5% positive (middle panel) after subtraction of
background fluorescence of cells transfected with empty vector
(black histogram in left panel). Fluorescent microscopy of
SmCD59.1 transfected cells (2006) shows typical membrane
fluorescence pattern (right panel). (B) Similar to (A), but using
CHO cells expressing hCD59 labeled with a rat MAb anti-hCD59
as positive control. Cells were 28.8% positive after background
subtraction from cells transfected with empty vector. (C) To
confirm GPI-anchor expression of SmCD59.1 in the cell surface,
CHO cells were treated (+) or not (2) with PiPL-C and stained
with anti-SmCD59.1 antibody. Percentage of fluorescent cells was
determined for both samples (top panels) after background
subtraction of cells transfected with empty vector. In bottom
panels, CHO cells transfected with hCD59 were tested as positive
control.
(PDF)
Table S1 Set of primers/probes used to detect gene
expression of SmCD59.1-7 by Real Time RT-PCR and
synthetic genes used in this study. aRedesigned sequence
using DNA2.0 codon optimization algorithms for expression in
Pichia pastoris. bRedesigned sequence using codon optimization
algorithms for expression in mammalian cells.
(PDF)
Table S2 List of organisms, abbreviations for gene
names and accession numbers used in this study.
Databases:*http://schistodb.net/schisto/, **http://bioinfosecond.
vet.unimelb.edu.au/ and ***http://smedgd.neuro.utah.edu/blast.
php
(PDF)
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